The IDENTIFY study : the investigation and detection of urological neoplasia in patients referred with suspected urinary tract cancer - a multicentre observational study
Author
Khadhouri, SinanGallagher, Kevin M
MacKenzie, Kenneth R
Shah, Taimur T
Gao, Chuanyu
Moore, Sacha
Zimmermann, Eleanor F
Edison, Eric
Jefferies, Matthew
Nambiar, Arjun
Mannas, Miles P
Lee, Taeweon
Marra, Giancarlo
Lillaz, Beatrice
Gómez Rivas, Juan
Olivier, Jonathan
Assmus, Mark A
Uçar, Taha
Claps, Francesco
Boltri, Matteo
Burnhope, Tara
Nkwam, Nkwam
Tanasescu, George
Boxall, Nicholas E
Downey, Alison P
Lal, Asim A
Antón-Juanilla, Marta
Clarke, Holly
Lau, David H W
Gillams, Kathryn
Crockett, Matthew
Nielsen, Matthew
Takwoingi, Yemisi
Chuchu, Naomi
O'Rourke, John
MacLennan, Graeme
McGrath, John S
Kasivisvanathan, Veeru
Publication date
2021-09-08
Metadata
Show full item recordAbstract
Objective: To evaluate the contemporary prevalence of urinary tract cancer (bladder cancer, upper tract urothelial cancer [UTUC] and renal cancer) in patients referred to secondary care with haematuria, adjusted for established patient risk markers and geographical variation. Patients and methods: This was an international multicentre prospective observational study. We included patients aged ≥16 years, referred to secondary care with suspected urinary tract cancer. Patients with a known or previous urological malignancy were excluded. We estimated the prevalence of bladder cancer, UTUC, renal cancer and prostate cancer; stratified by age, type of haematuria, sex, and smoking. We used a multivariable mixed-effects logistic regression to adjust cancer prevalence for age, type of haematuria, sex, smoking, hospitals, and countries. Results: Of the 11 059 patients assessed for eligibility, 10 896 were included from 110 hospitals across 26 countries. The overall adjusted cancer prevalence (n = 2257) was 28.2% (95% confidence interval [CI] 22.3-34.1), bladder cancer (n = 1951) 24.7% (95% CI 19.1-30.2), UTUC (n = 128) 1.14% (95% CI 0.77-1.52), renal cancer (n = 107) 1.05% (95% CI 0.80-1.29), and prostate cancer (n = 124) 1.75% (95% CI 1.32-2.18). The odds ratios for patient risk markers in the model for all cancers were: age 1.04 (95% CI 1.03-1.05; P < 0.001), visible haematuria 3.47 (95% CI 2.90-4.15; P < 0.001), male sex 1.30 (95% CI 1.14-1.50; P < 0.001), and smoking 2.70 (95% CI 2.30-3.18; P < 0.001). Conclusions: A better understanding of cancer prevalence across an international population is required to inform clinical guidelines. We are the first to report urinary tract cancer prevalence across an international population in patients referred to secondary care, adjusted for patient risk markers and geographical variation. Bladder cancer was the most prevalent disease. Visible haematuria was the strongest predictor for urinary tract cancer.Citation
Khadhouri S, Gallagher KM, MacKenzie KR, Shah TT, Gao C, Moore S, Zimmermann EF, Edison E, Jefferies M, Nambiar A, Mannas MP, Lee T, Marra G, Lillaz B, Gómez Rivas J, Olivier J, Assmus MA, Uçar T, Claps F, Boltri M, Burnhope T, Nkwam N, Tanasescu G, Boxall NE, Downey AP, Lal AA, Antón-Juanilla M, Clarke H, Lau DHW, Gillams K, Crockett M, Nielsen M, Takwoingi Y, Chuchu N, O'Rourke J, MacLennan G, McGrath JS, Kasivisvanathan V; IDENTIFY Study group. The IDENTIFY study: the investigation and detection of urological neoplasia in patients referred with suspected urinary tract cancer - a multicentre observational study. BJU Int. 2021 Oct;128(4):440-450. doi: 10.1111/bju.15483. Epub 2021 Sep 8Type
ArticleAdditional Links
http://onlinelibrary.wiley.com/journal/10.1111/(ISSN)1464-410XPMID
33991045Journal
BJU InternationalPublisher
Blackwell Scienceae974a485f413a2113503eed53cd6c53
10.1111/bju.15483